After Lengthy Delay, Polaris Ready To Take HCC Drug Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
With an SPA, the Taiwan-financed, U.S.-based biotech hopes to obtain FDA approval in hepatocellular carcinoma with a single Phase III trial.